Contrast Leakage Patterns from Dynamic Susceptibility Contrast Perfusion MRI in the Grading of Primary Pediatric Brain Tumors by Ho, Chang Y. et al.
Contrast Leakage Patterns from Dynamic Susceptibility Contrast 
Perfusion MRI in the Grading of Primary Pediatric Brain Tumors
Chang Y. Ho, Jeremy S. Cardinal, Aaron P. Kamer, Chen Lin, Stephen F Kralik 
Indiana University School of Medicine 
Department of Radiology 
Corresponding author: 
Chang Ho 
705 Riley Hospital Drive 
MRI department 
Indianapolis, IN 46202 
cyho@iupui.edu 
A portion of this work was presented at the ASNR 2014 annual meeting in Montreal, Canada 
_________________________________________________________________________________
 
This is the author's manuscript of the article published in final edited form as:
Ho, C. Y., Cardinal, J. S., Kamer, A. P., Lin, C., & Kralik, S. F. (2016). Contrast Leakage Patterns from Dynamic 
Susceptibility Contrast Perfusion MRI in the Grading of Primary Pediatric Brain Tumors. American Journal of 
Neuroradiology, 37(3), 544–551. https://doi.org/10.3174/ajnr.A4559
PURPOSE: To evaluate contrast leakage patterns from dynamic susceptibility contrast (DSC) 
tissue signal intensity time curves (TSITC) in grading pediatric brain tumors. 
MATERIALS AND METHODS: A retrospective review of TSITCs from 63 cases of pediatric 
brain tumors with preoperative DSC perfusion MRI was performed independently by two 
neuroradiologists. TSITCs were generated from ROIs placed in the highest perceived tumor 
rCBV.  The post-bolus portion of the curve was independently classified as returning to baseline, 
continuing above baseline (T1-dominant contrast leakage), or failing to return to baseline (T2*-
dominant contrast leakage). Inter-observer agreement of curve classification was evaluated using 
Cohen’s kappa. A consensus classification of curve type was obtained in discrepant cases, and 
the consensus classification was compared with tumor histology and World Health Organization 
grade. 
RESULTS: 
TSITC classification concordance was 0.69 (0.54 – 0.84) overall, and 0.79 (0.59 – 0.91) for a 
T1-dominant contrast leakage pattern. 25/25 tumors with consensus T1-dominant contrast 
leakage were low grade (PPV, 1.0; 0.83–1.00). By comparison, tumors with consensus T2*-
dominant contrast leakage or return to baseline were predominantly high grade (10/15 and 15/23 
respectively) with a high negative predictive value (1.0; 0.83-1.0).  For pilomyxoid or pilocytic 
astrocytomas, a T1-dominant leak demonstrates high sensitivity (0.91; 0.70-0.98) and specificity 
(0.90, 0.75-0.97).   
CONCLUSION: 
There is good inter-observer agreement in classification of DSC perfusion TSITCs for pediatric 
brain tumors, particularly for T1 dominant leakage. Among pediatric brain tumor patients, a T1-
dominant leakage pattern is highly specific for a low grade tumor, and demonstrates high 
sensitivity and specificity for pilocytic or pilomyxoid astrocytomas. 
ABBREVIATIONS: DSC = dynamic susceptibility contrast; ROI = region of interest; rCBV = 
relative cerebral blood volume; WHO = World Health Organization 
INTRODUCTION 
Primary brain tumors represent 29% of all childhood cancers, are the most common solid 
childhood tumor, and are the leading cause of cancer death in this age population [1].  With 
experienced pediatric neuroimaging specialists, presurgical diagnosis with anatomic MRI 
sequences can be accurate, especially with a classic appearance and location presentation.  
However, many primary neoplasms do not follow the classic imaging appearance and the use of 
advanced imaging techniques such as perfusion imaging, diffusion weighted imaging, and MR 
spectroscopy have been utilized to grade primary pediatric tumors [2-4]. 
Dynamic susceptibility contrast (DSC) perfusion MRI has demonstrated utility in the 
pretreatment evaluation of adult intracranial neoplasms for tumor grading, guiding biopsy, and 
prognosis. However, while the most common adult primary parenchymal neoplasms are of the 
astrocytic cell type, the most common pediatric primary brain tumors have diverse cellular 
origins, with astrocytic origin for pilocytic astrocytomas and embryonal neuroepithelial origin 
for medulloblastomas.  Even within astrocytomas, outside of the classic “cyst and mural nodule” 
appearance of pilocytic astrocytomas, there is some overlap in the radiographic and histological 
appearance of pilocytic astrocytomas and high grade gliomas, with relative cerebral volume 
(rCBV) demonstrating usefulness in distinguishing the two astrocytic entities [5].  However, 
when the most common pediatric primary brain tumors are evaluated, there is an overlapping 
range of rCBV values, particularly between pilocytic astrocytomas and medulloblastomas, 
limiting the usefulness of DSC perfusion in predicting low versus high grade tumors 
preoperatively [2].   
While rCBV has received the greatest attention in differentiating tumor grades from perfusion 
imaging in adult tumors [6-8], tissue signal intensity time curves (TSITC) have also 
demonstrated diagnostic utility, most notably in differentiating primary CNS lymphoma from 
glioblastoma multiforme and metastases [9-11]. We evaluate the inter-observer agreement of 
classification of DSC perfusion MRI TSITCs and the utility of curve classification as a tool for 
grading pediatric brain tumors. 
MATERIALS AND METHODS 
Following institutional review board approval, a retrospective radiology database search from 
September 2009 to August 2013 identified a total of 65 pediatric brain tumor patients with 
pathology-proven diagnosis and assigned World Health Organization (WHO) grade who had 
undergone DSC perfusion MRI on initial evaluation prior to chemotherapy, biopsy or surgical 
resection. In the majority of cases, a single dose of 2mg/kg IV dexamethasone was given 
emergently prior to MRI for the treatment of tumor associated cerebral edema.  A total of two 
cases were excluded for a total of 63 cases for review. One case was excluded due to poor 
contrast bolus and the second case was excluded due to significant susceptibility artifact 
generated by the patient’s dental braces.  This study population was previously reported [2].  
MR Imaging 
DSC perfusion MR images were obtained during the first pass of a bolus of gadobenate 
dimeglumine (MultiHance, Bracco Diagnostics Inc., Princeton, NJ) on 1.5T and 3T MRI 
scanners (Siemens Avanto and Verio, Erlangen, Germany) using a gradient echo echo planar 
sequence (TR 1410-2250 / TE 30 and 45 ms, flip angle 90 degrees). Two different TEs were 
utilized on different scanners.  A range of TR was adjusted for tumor coverage.  No cases were 
performed with a preload of IV contrast.  Following a pre-contrast phase to establish a baseline, a 
contrast medium dose of 0.1 mmol/kg of body weight was injected followed by a normal saline 
flush for a total volume of 32 ml. When possible, an 18 or 20 gauge peripheral intravenous 
access was used with a power injector rate of 5 ml/s. In some cases, primarily with smaller 
children, only 24 gauge peripheral intravenous access was possible.  Contrast bolus adequacy 
was evaluated by two fellowship-trained board-certified neuroradiologists with certificate of 
added qualification (C.H., 7 years experience, and S.K., 3 years experience) based on TSITCs 
and included or excluded in consensus. 
Data Analysis 
Using a commercially available workstation (Dynasuite Neuro 3.0, InVivo Corp, Pewaukee WI), 
each neuroradiologist independently selected multiple 3 to 5 mm2 ROIs within the tumor, placed 
at the locations of perceived highest rCBV using Dynasuite-generated rCBV maps, blinded to 
pathologic diagnosis. Anatomic MR imaging sequences were used to help define tumor location 
and avoid major blood vessels or hemorrhage when placing the ROI. The resulting signal 
intensity curve from the ROI with the highest rCBV was used for classification.  This technique 
has been previously described in the literature [2]. Use of the maximum rCBV for 
characterization of the TSITC ensures that the most perfused portion of a heterogeneous tumor is 
evaluated, reducing sampling errors.  Curves were assessed out to 50 TRs on the time axis.  A Y-
axis value prior to the first pass bolus was chosen to represent the average of the baseline and 
compared to the final Y axis value at 50TRs.  The portion of the curve following the first pass of 
contrast medium bolus was characterized as returning to a level within ± 10% of baseline with 
plateau (return to baseline Figure 1), overshooting at least 10% above baseline without plateau 
(T1-dominant contrast leakage; Figure 2), or failing to return to a level less than 10% below 
baseline (T2*-dominant contrast leakage; Figure 3).  Inter-observer agreement was assessed 
using Cohen’s kappa. Blinded consensus opinion was obtained in cases with discrepant curve 
classification, and the resulting TSITCs were compared with individual WHO tumor grade.  
TSITC results were also compared to the averaged rCBV maximum between the two observers.  
Histopathologic evaluation of surgical specimens for all tumors was performed by one of two 
board-certified neuropathologists who determined a diagnosis and assigned a WHO grade of I 
through IV.  
A Chi-square test of independence was used to assess for potential significant differences 
between 1.5T and 3.0T, 30ms and 45ms TE, range of TR, and dexamethasone administration.  
Diagnostic accuracy was assessed for specific curve patterns. 
Statistical analysis was performed using SPSS 21 (IBM Corp. Armonk, NY) and an online 
statistical calculator (Vassarstats, http://vassarstats.net/). 
RESULTS
Patient characteristics are summarized in table 1. There were 38 low grade (WHO grade I-II) 
tumors, and 25 high grade (WHO grade III-IV) tumors.  
Independent classification of TSITCs by two neuroradiologists had a Cohen’s kappa of 0.69 
(0.54 – 0.84) indicating good inter-observer agreement. Proportion of agreement was highest 
with T1-dominant pattern (0.79, 0.56-0.91) compared to T2*-dominant pattern (0.60, 0.39-0.78) 
and return to baseline (0.57, 0.35-0.76).  
The Chi-squared test for independence between 1.5T and 3.0T scanners (p=0.63), 30 and 45 TE 
(p=0.55), and TR range (p=0.14) failed to show significance indicating that the null hypothesis is 
not rejected, or, that leakage patterns are not dependent on the differences in magnet strength, TE 
or TR in our scanning parameters.  Dexamethasone, however did show some significant (p=0.02) 
effect.  Further Chi-squared analysis between tumors treated with dexamethasone (N=41) and 
without dexamethasone (N=22) showed a significant difference in all low grade tumors (p=0.03) 
but not with pilocytic astrocytomas (p=0.99), pilomyxoid astrocytomas (p=1.0) or both of the 
piloid tumors together (p=0.46).  For high grade tumors, dexamethasone also did not show a 
significant effect (p=0.09). 
All tumors 
Among 38 low grade tumors,  twenty-five had consensus classification of T1-dominant contrast 
leakage while thirteen had a consensus curve classification other than T1-dominant leakage--
either return to baseline or T2*-dominant leakage. The 25 tumors with T1-dominant contrast 
leakage included: 15 pilocytic astrocytomas, six pilomyxoid astrocytomas, one low grade 
glioneuronal tumor, one WHO grade 2 ependymoma, one desmoplastic infantile ganglioglioma, 
and one choroid plexus papilloma.  Tumors showing a consensus curve classification with T2*-
dominant leakage or return to baseline were predominantly high grade. Ten out of 15 tumors 
identified as having post-bolus curve with T2*-dominant leakage were high grade (positive 
predictive value, 0.67, 0.39 – 0.87), and 15 out of 23 tumors with curves identified as returning 
to baseline were high grade (positive predictive value, 0.65, 0.43 – 0.83).  Combining T2* and 
return to baseline patterns for high grade tumor yielded high sensitivity (1.0, 0.83-1.0) and 
negative predictive value (1.0, 0.83-1.0) at the cost of specificity (0.66, 0.49-0.80).  The most 
common high grade tumors such as medulloblastoma, anaplastic ependymoma, and glioblastoma 
had both T2* and baseline patterns.  All three cases of atypical teratoid rhabdoid tumor showed a 
return to baseline pattern.  Conversely, the most common low grade tumors such as pilocytic 
astrocytoma and pilomyxoid astrocytoma demonstrated predominantly T1-dominant leakage: 
15/17 for pilocytic astrocytoma and 6/6 for pilomyxoid astrocytoma.  One case out of three 
WHO II ependymomas showed T1-dominant leakage.  For the diagnosis of pilocytic or 
pilomyxoid astrocytoma, a T1-dominant leakage pattern yields a high sensitivity (0.91, 0.70-
0.98; negative predictive value, 0.95, 0.81-0.99) and specificity (0.90, 0.75-0.97; positive 
predictive value, 0.84, 0.63-0.95) [Table 2].      
An analysis of variance (ANOVA) showed no significant differences (p=0.11, F-ratio=2.32) 
between the means of the rCBV maximum for each leakage pattern (T1-dominant = 3.25 ± 3.3, 
Baseline = 3.25 ± 2.2, T2*-dominant =5 .18 ± 3.6).  A T-test between the means of rCBV 
maximum for T1-dominant leakage (3.25 ± 3.3) and T2*-dominant combined with baseline 
leakage patterns (4.02 ± 2.93) also yielded no significant difference (p=0.33).  Chi squared tests 
were performed for significant differences between WHO grade and TSITC leakage results.  
Grade I versus grade II tumors were not significant (p=0.38) nor was grade III versus grade IV 
tumors (p=0.93).  Only high (III and IV) versus low grade (I and II) were significant (p<0.0001).       
Dexamethasone group 
Among the forty-one patients with tumors that received dexamethasone prior to DSC perfusion 
MRI, nineteen had consensus T1-dominant leakage, twelve had a consensus T2*-dominant 
leakage pattern, and ten had a consensus return to baseline pattern. All nineteen with a T1-
dominant leakage pattern were low grade tumors while five other low grade tumors had a 
leakage pattern other than T1-dominant leakage.  Out of twelve tumors with T2*-dominant 
leakage, nine were high grade.  Out of ten tumors with return to baseline pattern, eight were high 
grade.  Thirteen out of fourteen pilocytic astrocytomas and three out of three pilomyxoid 
astrocytomas demonstrated T1-dominant leakage.  Diagnostic accuracy for this cohort is 
summarized in table 2.  Within the entire dexamethasone group, no significant differences were 
seen between magnet strengths (p=0.62), TE (p=0.32), or TR (p=0.20). 
No Dexamethasone group 
Among the twenty-two patients with tumors that did not receive dexamethasone prior to DSC 
perfusion MRI, six had a consensus T1-dominant leakage, three had a consensus T2*-dominant 
leakage, and thirteen had a consensus return to baseline pattern. All six tumors with a T1-
dominant leakage pattern were low grade tumors.  Eight low grade tumors had a leakage pattern 
other than T1-dominant leakage.  Out of three tumors with T2*-dominant leakage, only one was 
high grade.  Out of thirteen tumors with return to baseline pattern, seven were high grade.  Two 
out of three pilocytic astrocytomas and three out of three pilomyxoid astrocytomas demonstrated 
T1-dominant leakage.  Diagnostic accuracy is summarized in table 2.  Within the entire no 
dexamethasone group, no significant differences were seen between magnet strengths (p=0.08), 
TE (p=0.97), or TR (p=0.40). 
        
DISCUSSION 
 
In practice, hemodynamics, status of the blood-brain barrier, timing of the contrast bolus, and 
MR pulse sequence parameters affect the shape of the TSITC [12-16]. Disruption or lack of a 
blood-brain barrier results in leakage of contrast medium into the extravascular extracellular 
space. While in the intravascular space, paramagnetic contrast medium causes predominantly 
T2* effects with loss of MR signal, however once in the extravascular extracellular space, T1-
shortening effects compete with the T2* effects [15, 16]. Depending on the MR parameters and 
biological tissue environment, T1-shortening effects may predominate and cause a post bolus 
curve that returns to and then passes baseline, or T2* effects may predominate and result in a 
post bolus curve that fails to return to baseline [15]. Another mechanism for a curve that fails to 
return to baseline was suggested by Kassner et al who showed that residual T2* effects may 
reflect delayed passage of intravascular contrast medium due to vascular tortuosity, 
disorganization, and hypoperfusion in areas of increased neovascularity, comparing this effect to 
the tumor staining seen on catheter angiography [13].   
Previous authors describe the portion of the curve after the peak as percent signal recovery, [9, 
17] with a high percent signal recovery correlating with our T1-dominant leakage, and a low
percent signal recovery as T2*-dominant leakage, or with smaller T2* effects, a return to 
baseline.  Cha et al. demonstrate a significant difference between metastatic brain tumors and 
glioblastoma as well as the associated surrounding abnormal white matter in adults with greater 
T2* effects and less than 50% return to baseline for metastatic tumors compared to greater than 
75% recovery for glioblastoma.  They suggest that this difference is due to the lack of a blood 
brain barrier leading to greater uniform vascular permeability and leakage in metastatic tumors, 
compared to some presence of a blood brain barrier in glioblastomas, with less uniform vascular 
permeability [15].  Lastly, the balance between T1 and T2* effects is affected by varying MR 
parameters including the flip angle, TE and TR in gradient echo EPI DSC perfusion MRI [10, 
12, 13, 15, 16, 17]. We used a narrow range of TE for similar T2* effect across scanners and a 
uniform flip angle on all scanners for recovery from the peak.  Previous authors have used a low 
flip angle to suppress T1 signal effects [16, 17]; however in our study, our 90 degree flip angle 
does not sufficiently suppress the T1 signal for our range of TR to prevent overshoot of the 
baseline in most low grade tumors, which we categorized as T1-dominant leakage.   
Advances in knowledge 
A striking finding in our data was 100% positive predictive value (25 of 25) for low grade 
tumors if a T1-dominant leakage pattern was identified.   The converse is also true in that the 
lack of a T1 leak pattern (T2* or return to baseline) results in a 100% negative predictive value 
for high grade tumors.  T1-dominant leakage patterns were also sensitive and specific for either a 
pilocytic astrocytoma or pilomyxoid astrocytoma.  In addition, good interobserver agreement for 
identifying a T1-dominant leakage pattern was found, indicating significant potential clinical 
utility for grading pediatric brain tumors with TSITCs from DSC perfusion.  
Little prior data exists in the literature regarding the use of DSC perfusion MRI and signal 
intensity curves in the evaluation of pediatric brain tumors. Similar to our findings, Grand et al 
reported a series of 9 pilocytic astrocytomas evaluated with DSC perfusion MRI, in which all 9 
tumors demonstrated an overshoot of the baseline, or T1-dominant contrast leakage pattern [16]. 
Cha reported that pilocytic astrocytomas have > 70% signal recovery, while medulloblastomas 
have < 50% signal recovery, which is consistent with our findings [18]. 
Prior to our study, a T1-dominant leakage pattern has most notably been demonstrated in 
primary CNS lymphoma, and has been shown to be useful in distinguishing lymphoma from 
glioblastoma multiforme and CNS metastases [9-11].  Despite the lack of neoangiogenesis in 
CNS lymphoma, both glioblastoma and lymphoma have elevated rCBV, but have a significant 
difference in the high percent signal recovery for lymphomas.  This has been attributed to the 
characteristic perivascular invasion of lymphoma cells, leading to disruption of the basement 
membrane and resulting vascular permeability.  The hypercellularity of lymphoma with a small 
extravascular extracellular space has been suggested as a contributing factor although the exact 
mechanism for T1-dominant leakage effects in lymphoma is not well understood [9].  This 
finding contradicts the findings of Cha et al. in that the lack of a blood brain barrier in metastatic 
disease, with resulting vascular permeability results in a low percent recovery, or T2*-dominant 
effect rather than the T1-dominant effect in CNS lymphoma [9, 17].  Cha et al. used a flip angle 
of 35° compared to 80° for Mangla et al., which may contribute to the differing TSITC results.  
Biological factors may include differing rates of contrast leakage between CNS lymphoma and 
metastatic disease with a faster accumulation and concentration of extravascular contrast in 
metastatic disease leading to T2*-dominant effects.  The mechanism underlying the observed 
post-bolus T1-dominant effects in low-grade pediatric brain tumors is not known, but is also 
likely related to the balance between T1-shortening and T2* effects of paramagnetic contrast 
medium that has leaked into the extravascular extracellular space. Other factors affecting the T1- 
T2* balance may include characteristics of the extravascular space such as cellular density, water 
content, and other molecular constituents, in addition to hemodynamic flow issues and capillary 
permeability. 
Pilocytic astrocytomas and pilomyxoid astrocytomas account for 21 of the 25 tumors in our 
series demonstrating post-bolus T1-dominant leakage. Pilocytic astrocytomas are described as 
having biphasic histology with areas of loose glial tissue interposed with compacted piloid tissue 
composed of dense hypercellular sheets of elongated bipolar cells [20]. Distinguishing features 
of pilomyxoid astrocytomas include monomorphous piloid cells in a myxoid background with an 
angiocentric pattern, similar to perivascular pseudorosettes in ependymomas. While pilomyxoid 
astrocytomas tend to occur in younger children in the hypothalamic/ chiasmatic pathway, with 
more aggressive behavior, and a higher propensity for leptomeningeal spread, pilocytic and 
pilomyxoid astrocytomas have significant morphological and imaging overlap.  There have been 
reports of recurrent pilomyxoid tumors demonstrating pilocytic features after several years, with 
some authors suggesting that pilomyxoid astrocytoma may be an infantile form versus an 
extreme subtype of pilocytic astrocytoma [21-23]. It is because of this significant overlap, and 
the lack of distinguishing imaging characteristics between the two tumors that we calculated 
diagnostic accuracy with both tumors rather than separately. Vascular proliferation can be seen 
in the solid component of both tumors but with more mature endothelial cells in a single layer 
compared to glioblastomas [24, 25].  These single endothelial layers with open tight junctions 
and fenestrae as well as hyaline degeneration around vessels have been postulated to allow 
contrast medium extravasation and therefore vascular permeability [18].  Similar to CNS 
lymphomas, this level of increased vascular permeability likely plays a partial but crucial role in 
the T1-dominant leakage effects seen in both tumors.  Further research between different 
pediatric tumors using T1 signal based dynamic contrast enhancement MRI may be helpful in 
elucidating differences in vascular permeability. 
Affect of Dexamethasone on leakage patterns 
We could not control for the administration of dexamethasone on newly diagnosed brain tumor 
pediatric patients as corticosteroids are a first line emergent therapy for controlling the cerebral 
swelling and the resultant mass effect from mass occupying brain tumors.  In a previous work on 
the same patient population, there was no significance between patients with and without 
dexamethasone treatment and rCBV measurements [2].  However, given the known rapid effects 
of dexamethasone in decreasing capillary permeability and reducing vasogenic edema [26, 27], 
the significance between patient populations is not surprising.  However, only our low grade 
tumor group was significant, and there was larger proportion of T1-dominant and T2*-dominant 
leakage patterns within the dexamethasone group.  This result seems counterintuitive as high 
grade tumors typically have greater vasogenic edema and mass effect, and decreasing capillary 
permeability should trend toward the return to baseline pattern, as this pattern would best 
represent no leakage.  In reality, multiple physiological parameters likely affect the leakage 
pattern as indicated by our results.  Despite the significance of dexamethasone on the low grade 
tumor group, the 100% specificity of a T1-dominant leakage pattern for low grade pediatric 
tumors and high sensitivity and specificity for piloid astrocytomas remain unchanged for both 
groups with or without dexamethasone.    
Implications for patient care 
Despite uncertainty in the exact underlying mechanism, a T1-dominant contrast leakage pattern 
on the signal intensity curve obtained in the region of highest tumor rCBV is empirically highly 
predictive for low grade brain tumor in the pediatric population, while a T2*-dominant or 
baseline pattern has high sensitivity for a high grade tumor. In addition to rCBV data [2], 
TSITCs from DSC perfusion potentially offers additional information not otherwise apparent 
with routine anatomic MRI sequences. Recognition of a T1-dominant leakage pattern may 
improve accuracy in preoperatively predicting the presence of a low grade pediatric brain tumor.  
While experienced pediatric neuroradiologists can recognize low versus high grade tumors in the 
majority of cases, recognition of this pattern of perfusion leakage may be highly helpful in the 
minority of cases where low grade pilocytic or pilomyxoid astrocytomas become large and 
heterogeneous, mimicking higher grade neoplasms and conversely, when high grade 
astrocytomas have benign imaging features (Figures 1, 2).  Furthermore, when complete surgical 
resection is not possible, knowing the likelihood of a high grade or low grade tumor can guide 
how aggressive a neurosurgeon should be in debulking the tumor, at the risk of significant 
morbidity and mortality. 
Limitations 
The neuroradiologists evaluating the perfusion data were not blinded to the anatomic MRI 
sequences, some of which were highly suggestive of the tumor diagnosis. This was unavoidable 
because the anatomic images provide information integral in the assessment of the perfusion 
images (e.g. location of tumor, location of major vessels, etc.) This limitation is reasonable 
however, because it reflects the process in which MR perfusion images are evaluated in clinical 
practice. As noted in the discussion, a T1-dominant contrast leakage pattern has been described 
in CNS lymphoma and our series of 63 pediatric brain tumors included no cases of CNS 
lymphoma. While this represents a potential pitfall in using a T1-dominant leakage pattern to 
classify pediatric brain tumors as low grade, CNS lymphoma is rarely encountered in the 
pediatric population. Contrast medium infusion rate and peripheral intravenous catheter gauge 
are related issues that likely affect the quality of the perfusion study and are recognized 
challenges with performing DSC perfusion MRI on pediatric patients [28]. However, only one 
study out of the 65 identified by the search criteria was excluded for poor contrast medium bolus, 
indicating that high quality DSC perfusion MRI can be performed in pediatric brain tumor 
patients.  Differences in TR and TE parameters corresponded to studies obtained on different 
1.5T and 3.0T scanners and theoretically has some effect on signal intensity and 
recovery/leakage patterns. However, our analysis demonstrates no significant differences in our 
results attributable to these different field strengths or parameters.  It is important to note that 
there is no standardized criteria in the literature for T1 leak/T2* leak, or return to baseline. We 
arbitrarily chose the +/-10% range for the curve classification as a means of separation, and 
consequently curve classification could be altered if different thresholds are utilized. Similarly, 
as previously described, larger differences in technical parameters (flip angle, TE, TR) may 
result in greater differences in curve classification. 
CONCLUSIONS 
 
There is good interobserver agreement in classification of DSC perfusion tissue signal intensity 
time curves for pediatric brain tumors. Among our population of pediatric brain tumor patients, a 
T1-dominant leakage pattern is 100% specific for a low grade tumor and sensitive and specific 
for piloid astrocytomas, regardless of dexamethasone treatment.  The addition of tissue signal 
intensity time curves may help in cases where low grade tumors are large and heterogeneous, 
mimicking high grade neoplasms. 
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Table 1. Tumor pathology with patient age and TSITC results. 
Cases Age (years)
Tissue Signal Intensity 
Time Curve (TSITC) 
Classification
Average Range T1  Baseline T2
All cases  63  6.3 1.0 - 16.8 25  23 15
Infratentorial  39  5.6 1.2 - 14.2 16  13 10
Supratentorial  24  7.4 1.0 - 16.8 9  10 5
WHO 1  25  7.1 1.1 - 15.0 18  5  2
WHO 2  13  5.9 1.2 - 16.8 7  3  3
WHO 3  9  4.6 1.4 - 12.0 0  6  3
WHO 4  16  6.4 1.0 - 16.2 0  9  7
Pilocytic astrocytoma  17  7.3 2.2 - 15.0 15  1  1
Medulloblastoma  9  6.8 2.3 - 13.3 0  4  5
Ependymoma WHO 3  7  4.3 1.4 - 12.0 0  4  3
Pilomyxoid astrocytoma  6  2.9 1.2 - 5.8 6  0  0
Ependymoma WHO 2  3  2.2 1.5 - 2.9 1  0  2
ATRT  3  1.4 1.0 - 1.9 0  3  0
GBM  3  6.9 4.2 - 9.5 0  2  1
Choroid plexus 
papilloma  2  4.1 3.1 - 5.2 1  1  0
Fibrillary astrocytoma  1  4.3 0  1  0
Craniophayngioma  1  5.5 0  1  0
Desmoplastic infantile 
ganglioglioma  1  1.1 1  0  0
Ganglioglioma  1  12.9 0  1  0
Ganglion cell tumor  1  1.8 0  1  0
High grade diffuse 
glioma  1  6.9 0  1  0
Low grade glioma  1  12.8 0  0  1
Low grade glioneuronal 
tumor  1  11.5 1  0  0
Low-grade 
oligoastrocytoma  1  16.8 0  1  0
Oligodendroglioma  1  15.5 0  1  0
Pineal parenchymal 
tumor WHO 2  1  15.6 0  0  1
Supratentorial PNET  1  16.2 0  0  1
Anaplastic astrocytoma  1  4 0  1  0
 
 
  Sensitivity  Specificity  PPV  NPV 
T1 leakage 
pattern for low 
grade tumors 
66% (49-80%) 
79% (57-92%) 
43% (19-70%) 
100% (83-100%)
100% (77-100%) 
100% (60-100%) 
100% (83-100%) 
100% (79-100%) 
100% (52-100%) 
66% (49-80%) 
77% (54-91%) 
50% (26-74%) 
T2* leakage and 
baseline patterns 
for high grade 
tumors 
100% (83-100%) 
100% (77-100%) 
100% (60-100%) 
66% (49-80%) 
79% (57-92%) 
43% (19-70%) 
66% (49-80%) 
77% (54-91%) 
50% (26-74%) 
100% (83-100%)
100% (79-100%) 
100% (52-100%) 
T1 leakage for 
pilocytic and 
pilomyxoid 
astrocytomas 
91% (70-98%) 
94% (69-100%) 
83% (36-99%) 
90% (75-97%) 
88% (67-97%) 
94% (68-100%) 
84% (63-95%) 
84% (60-96%) 
83% (36-99%) 
95% (81-99%) 
95% (75-100%) 
94% (68-100%) 
 
Table 2. Diagnostic sensitivity of leakage patterns and tumors with 95% confidence intervals.  
PPV = positive predictive value.  NPV = Negative predictive value.  All tumors results are 
bolded, dexamethasone tumors results are italicized, and non-dexamethasone tumors results are 
normal font.  
Figure 1.  Axial T2 (A), axial T1 weighted post contrast (B), axial DSC perfusion CBV map (C), 
and tissue signal time intensity curve (D) of a glioblastoma.  The tumor has T2 hyperintensity, 
cystic change, minimal heterogeneous enhancement and has well circumscribed margins 
suggesting a low grade neoplasm such as a pilocytic astrocytoma.  However, the TSITC from a 
ROI with the highest tumoral rCBV demonstrates a return to baseline pattern, which is highly 
sensitive for a high grade tumor, and low probability that this represents a pilocytic or 
pilomyxoid astrocytoma.    
 
Figure 2. Axial T2 FLAIR (A), axial T1-weighted post contrast (B), axial DSC perfusion rCBV 
map (C), and tissue signal intensity time curve (D) of a pilocytic astrocytoma with atypical 
appearance. Despite apparent increased rCBV, poorly defined margins, central necrosis and 
surrounding T2 hyperintensity suggesting a high grade neoplasm, the T1-dominant leakage 
pattern suggests the correct interpretation of a low grade tumor.  The ROI is placed in the highest 
perfusing portion of the tumor not including a dominant central vessel.  
 
Figure 3. Axial T2 FLAIR (A), axial DSC perfusion rCBV map (B), and tissue signal intensity 
time curve (C) in a patient with medulloblastoma. The tissue signal intensity time curve 
demonstrates T2*-dominant contrast leakage following the contrast bolus. 
